Heron Therapeutics Inc HRTX

NAS: HRTX | ISIN: US4277461020   30/04/2025
2,420 USD (+3,42%)
(+3,42%)   30/04/2025

29 april 2025 · Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer · Persbericht

22 april 2025 · Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 · Persbericht

3 september 2024 · Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer · Persbericht

6 augustus 2024 · Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance · Persbericht

30 juli 2024 · Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 · Persbericht

15 juli 2024 · Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System · Persbericht

2 juli 2024 · Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") · Persbericht

29 mei 2024 · Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") · Persbericht

7 mei 2024 · Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates · Persbericht

24 april 2024 · Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 · Persbericht

11 april 2024 · Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City · Persbericht

28 maart 2024 · Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference · Persbericht

12 maart 2024 · Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates · Persbericht

28 februari 2024 · Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 · Persbericht

24 januari 2024 · Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures · Persbericht

7 januari 2024 · Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain · Persbericht

7 november 2023 · Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 · Persbericht

14 augustus 2023 · Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates · Persbericht

7 augustus 2023 · Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 · Persbericht

24 juli 2023 · Heron Therapeutics Announces Cost Reduction Plan and Restructuring · Persbericht

Mijn selecties